CRO reputation vital when selecting outsourcing partner; CEO

By Nick Taylor

- Last updated on GMT

Related tags: Contract research organization

Outsourcing to a well known CRO with a good reputation is vital to ensuring that data is well received by regulatory authorities, according to a CEO that just inked a deal for preclinical safety testing.

Speaking to Outsourcing-Pharma Rami Efrati, CEO of BrainStorm Cell Therapeutics, explained that his business will only outsource to well known companies because of the benefits they bring.

According to Efrati trials conducted at a well known and reputable contract research organisation (CRO) will be better received by regulatory authorities, which is an important factor for BrainStorm as it prepares to enter clinical trials.

BrainStorm has contracted Harlan Biotech Israel (HBI) to conduct safety trials of its amyotrophic lateral sclerosis in mice in preparation for applying to the Israeli Ministry of Health to conduct Phase I.

The decision to outsource was motivated by a lack of in-house capacity but Efrati added that even if BrainStorm had the capabilities he would have used a CRO.

This is in part motivated by the perceived benefits with regulatory agencies but also because Efrati believes there are advantages to having external personnel view the product and data.

Further outsourcing

The deal with HBI was preceded by a contract manufacturing deal with Protein Production Services (PPS), which will provide materials for the preclinical safety trial.

BrainStorm entered into the two contracts after it received funding from the Israeli government’s Office of the Chief Scientist and from a private investor, which enabled the company to commence the final preclinical steps.

Once this is complete BrainStorm intends to enter Phase I trials and Efrati said that further outsourcing will be needed at this stage. He explained that BrainStorm lacks the capacity to do clinical trials or manufacture current good manufacturing practice (cGMP) compliant materials.

Related news

Show more

Related products

show more

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more